Accellacare | Wilmington, Medical Center Drive
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one and a half year for each participant.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
800 participants in 2 patient groups
Loading...
Central trial contact
Novo Nordisk
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal